# Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex

> **NCT00532961** · PHASE4 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 310 (actual)

## Conditions studied

- Inflammation

## Interventions

- **DRUG:** Loteprednol etabonate 0.5% and tobramycin 0.3%
- **DRUG:** Dexamethasone 0.1% and tobramycin 0.3%

## Key facts

- **NCT ID:** NCT00532961
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-04
- **Final completion:** 2005-06
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2011-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532961, "Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00532961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*